Loss-of-Function Mutations in SWI/SNF Complexes Associated With Active Tumour Immune Microenvironment Clinical Response to Immune Checkpoint Blockade.

Zheng Yang, Zixuan Tian, Renji Liang, Yi Lu, Tengfei Zhu, Ya-Nan Wang, Wei Zhang

Abstract read

In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zheng YangDepartment of Pathology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.

Zixuan TianDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.

Renji LiangDepartment of Cardiothoracic Surgery, The First Affiliated Hospital of University of South China, Hengyang, China.

Yi LuDepartment of Data Science, Burning Rock Biotech, Guangzhou, China.

Tengfei ZhuDepartment of Data Science, Burning Rock Biotech, Guangzhou, China.

Ya-Nan WangDepartment of Pathology, Affiliated Hospital of Hebei University, Baoding, China.

Wei ZhangDepartment of Pathology, Beijing Hospital, National Center of Gerontology, Beijing, China.

Funding

National High Level Hospital Clinical Research Funding BJ-2022-144

6 · The paper itself

Abstract

Chromatin remodelling SWI/SNF complexes are recurrently altered in malignancies, and some members were found to be associated with immune checkpoint blockade (ICB) response. However, it is unclear whether SWI/SNF complex genes as a collective factor have clinical relevance. Through pan-cancer analysis of 8507 tumours across 26 types from The Cancer Genome Atlas, we demonstrate that SWI/SNF loss-of-function (LOF) mutations correlate with elevated immunogenicity markers, such as higher tumour mutational burden (TMB), neoantigen load, and microsatellite instability. SWI/SNF-LOF tumours exhibited enriched CD8

Indexed as

Chromosomal Proteins, Non-HistoneImmune Checkpoint InhibitorsLoss of Function MutationNeoplasmsTranscription FactorsTumor MicroenvironmentBiomarkers, TumorCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticHumansBiomarkers, TumorChromosomal Proteins, Non-HistoneImmune Checkpoint InhibitorsTranscription Factorsbiomarkercheckpoint blockadeloss‐of‐function mutationsSWI/SNF chromatin remodelling complexestumour microenvironment

Identifiers

PMID42642869

DOI10.1111/jcmm.71290

PMCPMC13507517

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.